Strongbridge Biopharma Stock Price, News & Analysis (NASDAQ:SBBP)

Strongbridge Biopharma trades on the NASDAQ under the ticker symbol "SBBP."

Strongbridge Biopharma plc (NASDAQ:SBBP) issued its quarterly earnings results on Wednesday, July, 31st. The biotechnology company reported ($0.30) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.31) by $0.01. The biotechnology company earned $6.08 million during the quarter, compared to the consensus estimate of $4.82 million. Strongbridge Biopharma had a net margin of 181.52% and a return on equity of 49.92%. View Strongbridge Biopharma's Earnings History.

Strongbridge Biopharma is scheduled to release their next quarterly earnings announcement on Wednesday, October 30th 2019. View Earnings Estimates for Strongbridge Biopharma.

Strongbridge Biopharma updated its FY 2019 earnings guidance on Wednesday, July, 31st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $18-20 million, compared to the consensus revenue estimate of $19.49 million.

4 analysts have issued twelve-month price targets for Strongbridge Biopharma's stock. Their predictions range from $11.00 to $15.00. On average, they anticipate Strongbridge Biopharma's share price to reach $12.6667 in the next twelve months. This suggests a possible upside of 372.6% from the stock's current price. View Analyst Price Targets for Strongbridge Biopharma.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Strongbridge Biopharma in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Strongbridge Biopharma.

Headlines about SBBP stock have trended negative on Friday, InfoTrie reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Strongbridge Biopharma earned a media sentiment score of -2.9 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Strongbridge Biopharma.

Strongbridge Biopharma saw a decline in short interest in August. As of August 31st, there was short interest totalling 1,125,500 shares, a decline of 16.2% from the July 31st total of 1,343,000 shares. Based on an average daily volume of 182,800 shares, the days-to-cover ratio is presently 6.2 days. Approximately 3.3% of the company's stock are sold short. View Strongbridge Biopharma's Current Options Chain.

Some companies that are related to Strongbridge Biopharma include Aurinia Pharmaceuticals (AUPH), Flexion Therapeutics (FLXN), Akebia Therapeutics (AKBA), DiaMedica Therapeutics (DMCAF), Milestone Pharmaceuticals (MIST), Myovant Sciences (MYOV), Lannett (LCI), Akero Therapeutics (AKRO), Retrophin (RTRX), Achillion Pharmaceuticals (ACHN), Basilea Pharmaceutica (BPMUF), Viking Therapeutics (VKTX), Akorn (AKRX), Urogen Pharma (URGN) and ImmunoGen (IMGN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Strongbridge Biopharma investors own include Energy Transfer LP Unit (ET), Dicerna Pharmaceuticals (DRNA), CBL & Associates Properties (CBL), Viking Therapeutics (VKTX), SunCoke Energy Partners (SXCP), Ocular Therapeutix (OCUL), Abeona Therapeutics (ABEO), Sorrento Therapeutics (SRNE), Verastem (VSTM) and Cornerstone Total Return Fund (CRF).

Strongbridge Biopharma's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.22%), D. E. Shaw & Co. Inc. (1.75%), River & Mercantile Asset Management LLP (0.85%), River & Mercantile Asset Management LLP (0.85%), Renaissance Technologies LLC (0.31%) and Stonepine Capital Management LLC (0.30%). View Institutional Ownership Trends for Strongbridge Biopharma.

SBBP stock was sold by a variety of institutional investors in the last quarter, including Park West Asset Management LLC, Wells Fargo & Company MN, Jefferies Group LLC and Stonepine Capital Management LLC. View Insider Buying and Selling for Strongbridge Biopharma.

SBBP stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., River & Mercantile Asset Management LLP, River & Mercantile Asset Management LLP, D. E. Shaw & Co. Inc., Renaissance Technologies LLC, Bank of New York Mellon Corp, Susquehanna International Group LLP and Vanguard Group Inc.. View Insider Buying and Selling for Strongbridge Biopharma.

Shares of SBBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SBBP stock can currently be purchased for approximately $2.68.

Strongbridge Biopharma has a market capitalization of $145.22 million and generates $18.03 million in revenue each year. The biotechnology company earns $31.85 million in net income (profit) each year or $0.31 on an earnings per share basis. Strongbridge Biopharma employs 106 workers across the globe.View Additional Information About Strongbridge Biopharma.

The official website for Strongbridge Biopharma is http://www.strongbridgebio.com/.

Strongbridge Biopharma's mailing address is 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053. The biotechnology company can be reached via phone at 610-254-9200 or via email at [email protected]